PNC-27
Also known as p53-penetratin chimeric peptide, PNC27
A chimeric p53-derived research peptide that binds membrane-bound HDM-2 to selectively lyse cancer cells in preclinical (in-vitro/animal) studies only.
Typical use cases
Dosing guidelines
Titration
Not applicable — a preclinical research compound, no human regimen.
Reconstitution
5 mg vial: ~1–2 mL bacteriostatic water yields ~2.5–5 mg/mL (for laboratory handling only).
Injection sites
No established human route; animal studies have used intraperitoneal/parenteral administration.
Storage & handling
Lyophilized: stable months cool/dark, longer frozen. Reconstituted: refrigerate (2–8 °C).
Side effects
- No human safety data (preclinical research compound)
Research summary
PNC-27 is a chimeric peptide combining a p53 HDM-2-binding domain with a membrane-penetrating leader sequence; it is reported to bind HDM-2 anomalously present in cancer-cell membranes, forming pores that cause selective membranolysis while sparing normal cells in laboratory models. All evidence is preclinical (cell culture and animal studies), with no completed human clinical trials, no established human dosing, and no human safety data. This is an investigational anticancer research peptide only and makes no therapeutic claim. Educational only — not medical advice.
Key references
- Sarafraz-Yazdi et al., PNAS (2010) — PNC-27 adopts an HDM-2-binding conformation and kills cancer cells via membrane HDM-2
- Bowne et al., Biomedicines (2022) — PNC-27 binds HDM-2 and induces selective membrane-pore formation
Related compounds
Where to buy
These are affiliate links. Purchasing through them helps support DoseForge at no extra cost to you.
Educational reference only — not medical advice. Dosing figures are commonly-cited ranges, not prescriptions. Consult a qualified clinician.
Log doses, rotate sites, watch your progress — free.